Search Results 171-180 of 17522 for Metformin

1. A Study To Evaluate The Safety And Effectiveness Of The Drug TTP399 To Target A1c In Type 2 Diabetics - Mayo Clinic

   On a stable (for the last 3 months prior to screening) regimen of metformin monotherapy equivalent of at least 1000 mg once daily. Males, females of ...

2. Drugs and Supplements that Start with G - Mayo Clinic

   Glipizide and metformin (oral route) · Glofitamab-gxbm (intravenous route). Gloperba. Also known as. Colchicine (oral route). Glucagen. Also known as. Glucagon ...

3. Investigational Extended Wear Insulin Infusion Set During Home Use for Type 1 Diabetes - Mayo Clinic

   Concurrent use of any non-insulin glucose-lowering agent, other than metformin (for example, GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, ...

4. Pioglitazone Versus Empagliflozin For Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus - Mayo Clinic

   * Fasting plasma glucose <220 mg/dL at screening visit. * Not on any antihyperglycemic medication except Metformin * Willing to perform blood glucose and ...

5. Importance of pre-pregnancy care for women with diabetes: A case from the endocrine teaching clinics

   With the exception of metformin and insulin, all glucose-lowering agents should be discontinued. Previously, NPH insulin and regular insulin were typically ...

6. Liraglutide (subcutaneous route) - Side effects & dosage - Mayo Clinic

   However, low blood sugar can occur when you use liraglutide with other medicines that can lower blood sugar, such as insulin, metformin, or a sulfonylurea.

7. The International Diabetes Closed Loop Trial DCLP4 - Mayo Clinic

   Use of Afrezza or any non-insulin glucose-lowering agent other than metformin (including GLP-1 agonists, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas) ...

8. A Study of How Common Bile Acid Malabsorption is in Patients with Diarrhea Predominant Irritable Bowel Syndrome - Mayo Clinic

   Participation eligibility · Birth control pill, estrogen replacement therapy, metformin and thyroxine replacement are permissible exceptions · Agents that alter ...

9. Ovarian Cancer Clinical Trials - Mayo Clinic Research

   Patients will be, in the opinion of the Investigator, appropriate for single-agent therapy for their next line of therapy. Metformin ... This randomized phase II ...

10. A Study To Explore The Renal Safety Of Visipaque Injection 320 MgI/mL In Patients With Chronic Kidney Disease - Mayo Clinic

    ... metformin is resumed). Has been exposed to any intravascular iodinated contrast medium in the 7 14 days prior to the Baseline Visit. Has congestive heart ...